Vaxcyte, Inc. (PCVX) CFO exercises options, sells 10,000 shares
Rhea-AI Filing Summary
Vaxcyte, Inc. president and CFO Andrew Guggenhime exercised stock options for 10,000 shares of common stock at $5.35 per share on August 3, 2026, then reported sales of 6,956 shares at a weighted-average price of $53.761 and 3,044 shares at $54.178 under a Rule 10b5-1 trading plan adopted March 4, 2026. After these transactions he directly held 216,827 stock options and indirectly held 61,850 common shares through ALG 2025 GRAT HOLDINGS LLC, while his direct common stock position includes 781 shares acquired under the Employee Stock Purchase Plan on May 15, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($485K approx. pre-tax spread)
Exercise and Sale
5 txns
Insider
GUGGENHIME ANDREW
Role
PRESIDENT AND CFO
Sold
10,000 shs ($539K)
Approx. gross sale proceeds
$539K
Approx. exercise cost
$54K
Approx. pre-tax spread
$485K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) F6 | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock F1 | 10,000 | $5.35 | $54K |
| Sale | Common Stock F2, F3 | 6,956 | $53.761 | $374K |
| Sale | Common Stock F2, F4 | 3,044 | $54.178 | $165K |
| holding | Common Stock F5 | -- | -- | -- |
Holdings After Transaction:
Stock Option (right to buy) — 216,827 shares (Direct);
Common Stock — 105,176 shares (Direct);
Common Stock — 61,850 shares (Indirect, See Footnote)
Footnotes (6)
- F1. Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026.
- F2. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 4, 2026.
- F3. The price reported is a weighted-average price. The shares were sold at prices ranging from $53.06 to $54.05. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4. The price reported is a weighted-average price. The shares were sold at prices ranging from $54.07 to $54.44. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F5. Shares are held by ALG 2025 GRAT HOLDINGS LLC, of which 100% of the limited liability company interest is owned by a grantor retained annuity trust, of which the Reporting Person is the annuitant and the trustee.
- F6. Option is fully vested and exercisable.
Key Figures
Options exercised: 10,000 shares
Shares sold: 10,000 shares
Sale tranche 1 price: $53.761 per share
+4 more
7 metrics
Options exercised
10,000 shares
Stock options exercised on August 3, 2026 at $5.35 per share
Shares sold
10,000 shares
Common shares sold on August 3, 2026 in two transactions reported with code S
Sale tranche 1 price
$53.761 per share
Weighted-average price for 6,956 shares sold; trade prices ranged from $53.06 to $54.05
Sale tranche 2 price
$54.178 per share
Weighted-average price for 3,044 shares sold; trade prices ranged from $54.07 to $54.44
Options remaining
216,827 shares
Stock options directly held after the August 3, 2026 option exercise
Indirect common shares
61,850 shares
Common shares held indirectly through ALG 2025 GRAT HOLDINGS LLC after the reported transactions
ESPP shares
781 shares
Common shares acquired under the Employee Stock Purchase Plan on May 15, 2026
Key Terms
Rule 10b5-1 trading plan, grantor retained annuity trust, weighted-average price, Employee Stock Purchase Plan, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
grantor retained annuity trust financial
"100% of the limited liability company interest is owned by a grantor retained annuity trust"
A grantor retained annuity trust (GRAT) is an estate-planning tool where the person who creates the trust transfers assets into it but receives fixed cash payments (an annuity) from the trust for a set number of years; whatever remains after that term passes to designated beneficiaries. It matters to investors because it can shift future appreciation of assets out of the creator’s taxable estate—like putting an asset into a timed vending machine that pays you fixed amounts while any extra value that grows inside the machine goes to heirs with reduced gift or estate tax consequences.
weighted-average price financial
"The price reported is a weighted-average price. The shares were sold at prices ranging"
Weighted-average price is the average of multiple prices where each price is counted according to its size or importance—larger trades carry more weight than smaller ones, like averaging course grades by credit hours. It matters to investors because it gives a more realistic picture of the true price paid or received, helping assess trade execution, compare performance, calculate cost basis, and value positions more accurately than a simple average.
Employee Stock Purchase Plan financial
"Includes 781 shares acquired under the Issuer's Employee Stock Purchase Plan on May 15, 2026."
An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.
Stock Option (right to buy) financial
"security_title": "Stock Option (right to buy)""
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transactions did Vaxcyte (PCVX) report for Andrew Guggenhime?
Andrew Guggenhime exercised 10,000 stock options at $5.35 per share on August 3, 2026 and reported sales of 10,000 common shares that same day in two transactions, with prices disclosed as weighted averages, under a Rule 10b5-1 trading plan.
Were the Vaxcyte (PCVX) insider sales made under a Rule 10b5-1 trading plan?
Yes. A footnote states the sales reported for Andrew Guggenhime were effected pursuant to a Rule 10b5-1 trading plan adopted on March 4, 2026, and the filing’s Rule 10b5-1 checkbox is marked as affirming plan-based transactions.
What Vaxcyte (PCVX) equity does Andrew Guggenhime hold after these transactions?
After the reported activity, he directly held 216,827 stock options and indirectly held 61,850 common shares through ALG 2025 GRAT HOLDINGS LLC. His direct common stock position also includes 781 shares acquired via the Employee Stock Purchase Plan on May 15, 2026.
What is ALG 2025 GRAT HOLDINGS LLC in relation to Vaxcyte (PCVX) insider ownership?
ALG 2025 GRAT HOLDINGS LLC holds 61,850 Vaxcyte common shares. One footnote explains that 100% of its interests are owned by a grantor retained annuity trust for which Andrew Guggenhime is both annuitant and trustee, so these shares are reported as indirectly owned.
What are the terms of the Vaxcyte (PCVX) stock options exercised by Andrew Guggenhime?
He exercised options covering 10,000 shares of common stock at an exercise price of $5.35 per share. The option is described as fully vested and exercisable and carries an expiration date of May 11, 2030 for the remaining option balance.